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Background: Thoughtful use of assessment tools to monitor disease requires an understanding of clinimetric
properties. These properties are often under-reported and, thus, potentially overlooked in the clinic. This study
aimed to determine the minimal detectable change (MDC) and coefficient of variation per cent (CV%) for tools
commonly used to assess the symptomatic and functional severity of knee and hip osteoarthritis.
Methods: We performed a test-retest study on 136 people awaiting knee or hip arthroplasty at one of two hospitals.
The MDC95 (the range over which the difference [change] for 95% of patients is expected to lie) and the coefficient of
variation per cent (CV%) for the visual analogue scale (VAS) for joint pain, the six-minute walk test (6MWT), the
timed up-and-go (TUG) test, the Knee Injury and Osteoarthritis Outcome Score (KOOS) and the Hip Disability
and Osteoarthritis Outcome Score (HOOS) subscales were calculated.
Results: Knee cohort (n = 75) - The MDC95 and CV% values were as follows: VAS 2.8 cm, 15%; 6MWT 79 m, 8%;
TUG +/−36.7%, 13%; KOOS pain 20.2, 19%; KOOS symptoms 24.1, 22%; KOOS activities of daily living 20.8, 17%;
KOOS quality of life 26.6, 44. Hip cohort (n = 61) - The MDC95 and CV% values were as follows: VAS 3.3 cm, 17%;
6MWT 81.5 m, 9%; TUG +/−44.6%, 16%; HOOS pain 21.6, 22%; HOOS symptoms 22.7, 19%; HOOS activities of daily
living 17.7, 17%; HOOS quality of life 24.4, 43%.
Conclusions: Distinguishing real change from error is difficult in people with severe osteoarthritis. The 6MWT
demonstrates the smallest measurement error amongst a range of tools commonly used to assess disease severity,
thus, has the capacity to detect the smallest real change above measurement error in everyday clinical practice.
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Though there is no gold standard for monitoring the
progression of knee or hip osteoarthritis (OA), there is
value in monitoring the disease [1,2]. Knowledge of the
trajectory of disease progression provides clinicians and
patients with benchmarks against which the effectiveness
of everyday self-management strategies [3] or clinician-
provided interventions can be evaluated [1,2]. Further-
more, the timing of knee or hip arthroplasty for people* Correspondence: Justine.Naylor@sswahs.nsw.gov.au
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unless otherwise stated.with OA may also be informed by capturing significant
deterioration in various health domains of those waitlisted
for surgery when wait times are protracted. For example,
those waitlisted for surgery may be escalated if there is
documented evidence of significant decline since first
consenting to the procedure.
There are multiple tools available which capture disease
severity based on the symptoms and impairments associ-
ated with OA. These include tests of physical function and
mobility as well as patient-reported surveys. Thoughtful
monitoring of the clinical severity of OA in an individual
using these tools requires knowledge of what changes
measured by these tools can be considered real. In order
to arrive at a decision, the clinician must first be cognisantLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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considered to be more than simple measurement error
[4]. This minimum change is referred to as the minimal
detectable change (MDC) [5-7] or smallest detectable
change (SDC) [4,8,9] and is mathematically (linearly)
related to the error of the measurement. Put simply,
the MDC or the SDC reflects the smallest within-person
change in score that can be interpreted as real and statisti-
cally significant [8]. In terms of clinimetrics, the MDC is a
metric for reproducibility (specifically, a measure of agree-
ment), and is determined by performing repeat measure-
ments on patients over a short period of time [8]. The
short time interval renders significant clinical change
between assessments unlikely [8], and it also avoids the
problem of response shift - a change in the meaning or a
recalibration of an outcome - if the tool captures a
patient-reported outcome [10].
Despite their obvious value in interpreting real change
at the level of the individual, several recent reviews of
tools used to assess OA and arthroplasty patients sug-
gest that the measurement error and MDC for the tools
are under-reported or underexplored [11-16]. This study,
therefore, aimed to evaluate the MDC of tools commonly
used to assess the symptomatic and functional severity of
knee or hip OA. Specifically, using a test-retest design, we
determined the MDC for the visual analogue scale for
pain (VAS Pain) [1,17,18], the timed up-and-go (TUG)
test [19], the six-minute walk test (6MWT) [20], the Knee
Injury and Osteoarthritis Outcome Score (KOOS) [21]
and the Hip Disability and Osteoarthritis Outcome Score
(HOOS) [22] in individuals with severe OA. As a secondary
aim, we also compared the MDCs for the different tools as
the magnitude of error may influence the choice of tool
used. The tools included were chosen by a multidisciplinary
working party overseeing a State-wide program primarily
intended to screen, treat and monitor patients with severe
knee or hip OA waitlisted for arthroplasty surgery - the
Osteoarthritis Chronic Care Program (OACCP) [23].
Methods
Study design and participants
A test-retest study involving individuals waitlisted for
total knee arthroplasty (TKA) or total hip arthroplasty
(THA) at one of two teaching hospitals was undertaken.
Individuals meeting the following eligibility criteria were
invited to participate: OA in the index joint; waitlisted
within the previous two months; and willingness to attend
two assessments separated by a 1-week interval. Partici-
pants were ineligible if they were unable to comprehend
the study protocol either because of an English language
limitation or because of documented dementia, or if they
intended to change pharmacological or physical manage-
ment of their OA within the next week. Participants who
reported an exacerbation of symptoms or had an acuteillness at the first or second assessment were also subse-
quently deemed ineligible. The study was approved by
The Nepean Blue Mountains Lead Human Research Ethics
Committee and all participants provided written, informed
consent.
Study protocol
As per current practice, administrative staff contacted all
waitlisted individuals via telephone to provide them with
an appointment to the chronic care program for assess-
ment of their joint status and overview of their arthritis
management. Those meeting the inclusion criteria for
the study were invited to be assessed twice for the pur-
poses of the study. Those agreeing to participate were
subsequently screened again by a researcher at the first
assessment. Co-morbidities, medication lists, and radi-
ology reports were reviewed as per the screening protocol
for the OACCP [23]. Eligible participants then completed
timed walk tests and several patient-reported measures.
Simple yet standardised instructions regarding the com-
pletion of the walk tests and patient-reported measures
were given as per the program’s procedure manual. The
participant was instructed to interpret the surveys in the
same way when they repeated them the following week
and to wear the same footwear. As recommended for
test-retest studies [4], the participant was scheduled an-
other appointment one week later, with a maximum
time between appointments of 10 days. A physiotherap-
ist at each hospital attached to the waitlist assessment
clinic undertook the second assessment, following the
same testing procedures. By having a different tester
undertake the second assessment, observer independ-
ence (from first to second measurement) was ensured
[24,25]. Time of testing (morning or afternoon), as per
usual clinical practice, was not standardised. Recruitment
and testing of participants were staggered across the two
sites such that both were completed at the first hospital
prior to their commencement at the second.
Specific tests
VAS for joint pain
Numerical scales for pain ranging from 0–10 appear to
have fairly consistent interpretation across disease states
[1]. Significant disability appears to emerge at scores
greater than five (moderate degrees of pain) [1]. Partici-
pants were asked to mark the pain they felt in their index
joint on average over the past week on a 10 cm scale an-
chored by ‘none’ to ‘extreme’. On both weeks, this was
completed prior to the walk tests.
Timed mobility
Timed mobility was assessed using the TUG [19] and the
6MWT [20]. Both these tests are recognised performance-
based tests for people with OA or who have undergone
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an armchair (45 cm seat height); the time taken (seconds)
to stand from sitting, walk three 3 meters as fast and safely
as possible with or without a walking aid, turn, return to
the chair and sit down was assessed. A minimum two tests
was performed with the fastest time included in the ana-
lysis. The 6MWT was conducted on a 30 m flat track. Par-
ticipants were instructed to perform each lap ‘as fast, but
safely as possible’ and asked not to stop at each end unless
a rest was required [29]. Participants walked alone unless
they were deemed unsafe; walking aids were permitted if
aids were typically used. The assessor provided standardised
verbal encouragement at the end of each 2-lap set. As rec-
ommended [20], a practise 6MWT was conducted. This oc-
curred prior to the completion of the surveys. A second
test (the test to be included in the analysis as the Week 1
test) was conducted a minimum 30 minutes later, the de-
finitive time dependent upon the individual’s symptomatic
recovery. Distance covered was recorded in meters.
Joint-specific surveys
Patient-reported outcomes are commonly used to cap-
ture joint-specific pain and function. The KOOS [21] and
the HOOS [22] were used here, both derived from the
Western Ontario and McMaster Universities Osteoarth-
ritis Index (WOMAC) and developed to capture higher
level improvement in younger or more active knee or hip
patients. Both surveys have been shown to have face and
construct validity and are responsive across a range of
conditions [12,13,21,22,30]. Whilst the aforementioned
VAS for pain was used to capture average joint pain
experienced across the week, the KOOS and HOOS
capture pain (and impairment) in specific contexts.
The surveys include 42 (KOOS) and 40 (HOOS) items
covering five patient-relevant joint-related health di-
mensions referenced to ‘the last week’: Pain (KOOS 9
items, HOOS 10 items), Other Disease-Specific Symp-
toms (7,5), Activities of daily living (ADL) Function
(17,17), Sport and Recreation Function (5,4), and
joint-related Quality of Life (QOL) (4,4). Each item’s
response is framed within a 5-point Likert scale, ran-
ging from 0 (No Problems) to 4 (Extreme Problems).
Each of the five scores is calculated as the sum of the
items included. Within each dimension, scores are trans-
formed to a 0–100 scale, with zero representing ex-
treme joint problems and 100 representing no joint
problems. In the present study, a priori, the Sport and
Recreation Function dimension was excluded based on
the knowledge (our own experience and the experience
of the developers [21]) that few people wait-listed for
arthroplasty engage in higher-level recreational activ-
ity, consequently the items (particularly for the KOOS)
are generally viewed as less important compared to
items in other dimensions [30].Though not part of the OACCP, the Oxford Knee and
Hip Scores (OKS, OHS) [31] were also added to the
test protocol for research purposes. For brevity, the re-
producibility results of the OKS and OHS are reported
elsewhere [32].Sample size and statistical analyses
A minimum 50 subjects is a general recommendation
for reproducibility studies [33]. Thus, a minimum 50
people with knee OA and 50 with hip OA were planned.
As the rate of knee surgery is greater than that for hip
surgery at both sites, we anticipated a greater sample for
the knee cohort in the timeframe available for recruit-
ment. The presence of systematic bias across the two
weeks was investigated using paired t-tests and the rela-
tionship between variability (error) and raw score was
inspected using Bland and Altman plots [24,25,31]. The
MDC for the walk tests and survey scores between the
two test days (Week 1 and Week 2) were determined as
described below.
For each measure, we calculated the standard error of
measurement (SEM) and the 95% confidence interval
[34,35]. We also estimated the 90% confidence interval
for a score, which is calculated as 1.645 × SEM; this
measure can be used to obtain a 90% confidence interval
for an individual’s measurement. Then, for each meas-
ure, we calculated the MDC at two levels of confidence,
MDC90=1.645 × √2× SEM, and MDC95 = 1.96 × √2× SEM .
The MDC90 and the MDC95 indicate that the difference
in two measurements for about 90% and 95% of patients
respectively will lie in this range. We determined the
values at two levels of confidence to aid comparison with
the literature. We note that the MDC95 provides the same
limits of agreement (LOA) as the Bland and Altman
method for assessing agreement [8]. In order to compare
agreement indices between tools, we calculated the co-
efficient of variation per cent (CV%) using the SEM divided
by the Week 1 average [36] multiplied by 100.
For all outcome variables we checked graphically that
the distribution of measurements did not strongly violate
the assumption of normality using histograms and Q-Q
plots. We found a violation of this assumption for the
variable QOL, which was strongly right-skewed. Due to
the presence of zero values on the scale, we did not log-
transform the QOL data to improve the distribution [25].
For TUG, using the Bland and Altman plots, we found
that the variability in measurements was proportional to
their level. Therefore, we log-transformed the TUG data
[25] and we estimated the MDC90 and MDC95 based on
this. In this case, the MDC90 and MDC95 provide an inter-
val in which the ratio of the two measurements for 90%
and 95% of patients will lie. We also calculated the coeffi-













Age, years, mean (sd) 67.6 (9.4) 65.2 (10.2)
Female, n (%) 47 (63) 33 (54)
Body Mass Index, kg/m2,
mean (sd)
33.7 (7.4) 30.9 (6.4)
At least 1 co-morbidity, n (%) 61 (83) 54 (89)
Cardiovascular 50 43
Diabetes Mellitus 20 14
Thyroid 8 4
Respiratory 6 9
Central nervous system 2 4
Kidney 2 2
Other 13 16
Other lower limb or
lumbar spine impairment
39 (52%) 29 (48%)
Previous knee or hip
arthroplasty
17 (23%) 12 (20%)
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nally, we re-estimated the MDC90 and MDC95 for TUG
after omitting an outlying observation (for which TUG
was 99.9 s for one hip cohort measurement).
All analyses were conducted using Stata version 13.1,
College Station, TX and the study adhered to the guide-
lines for qualitative research (http://www.biomedcentral.
com/authors/rats).
Results
Over the study period (July – October 2011 Hospital 1,
October 2011 – May 2012 Hospital 2), 260 people (n = 187
knee, n = 73 hip) were waitlisted for surgery. One hundred
and ninety-five were eligible to participate; 148 of these
consented (n = 80 knee, n = 68 hip) and 47 were unable due
to work commitments or transport limitations. Sixty-five
were ineligible (n = 17 non – OA, n = 48 non-English
speaking). Of those who provided consent, 136 (n = 75
knee; n = 61 hip) attended both assessment sessions; 12
people did not have their second assessment due to illness
or transport unavailability. The characteristics of the
retained cohort and those for whom repeat data were
not available were similar (Table 1). The demographic and
health profile of the definitive cohort are summarised in
Table 2.
Practise 6MWT and missing data
One hundred and fifteen participants (68 of 75 knee par-
ticipants, 47 of 61 hip participants) (85%) performed a
practise 6MWT on the first testing day prior to undertak-
ing the ‘included’ Week 1 6MWT; 21 were unwilling to
repeat the test on the same day. There were no significant
differences between the practise and included 6MWTs for
either the knee [346.8 (101.0) vs 350.9 m (104.0), p = 0.34]
or hip cohort [347.5 m (109.7) vs 343.5 (108.0), p = 0.28].
Thus, participants who did not complete a practise test
remained included in the week-to-week analyses.
Complete week-to-week data sets were not available








Age, yr, mean (sd) 66.5 (9.8) 67.8 (8.6) 0.62
Female, n (%) 80 (59) 9 (75) 0.36
Body Mass Index,
kg/m2, mean (sd)
32.5 (7.0) 32.7 (8.8) 0.94
Timed Up-and-Go, s 14.0 (8.1) 16.7 (10.6) 0.61
Six-minute walk test, m 332.2 (112.5) 250.2 (84.9) 0.10
Visual analogue scale,
Pain (index joint), cm
6.7 (2.0) 6.4 (1.6) 0.46
*Independent sample t-tests or Fisher’s Exact Test; sd, standard deviation.to repeat the 6MWT or the TUG the second week and
some did not complete every survey or VAS pain scale
at the second assessment due to an administration error.
Of those who did complete all surveys, there were no
occasions of missing data as all surveys were checked at
the time. The minimum sample size analysed for any
one tool was 68 and 54 for the knee and hip cohorts
respectively.
MDC
The error and agreement indices, including the SEM,
the MDC and the CV% are summarised in Table 3.
There were no or minor differences between the means
of each test across the weeks (Table 3) and, with the
exception of the TUG, the week-to-week differences were
not related to the raw scores across the available range.
Figures 1 and 2 illustrate the LOA for each tool assessed.
The 6MWT demonstrated the lowest error from week-to-
week for both the knee and hip cohorts; subsequently, the
CV% (knee, 8%; hip, 9%) were the lowest. As the measure-
ment error of TUG was related to level, we report the
ratio (week 1 to week 2) in which 90% and 95% of mea-
surements should lie. For knees, the MDC90 and MDC95
for TUG were ±30.8% and 36.7%, meaning that 90% and
95% of repeat measurements will be within about ±31%
and 37% of the original measurement in stable patients re-
spectively. For hips, the MDC90 and MDC95 were ±37.5%
and 44.6%, meaning that 90% and 95% of repeat measure-
ments for TUG will be within ±38% and 45% of the ori-
ginal measurement in stable patients, respectively. After
removing the patient’s measurements who had a TUG of













6MWT (m) n = 72 344.9 (105.6) 348.4 (102.3) −3.5 (40.3) 28.5 (24.5 to 34.1) 46.9 66.3 79.0 8
TUG* (s), n = 74 12.7 (4.7) 13.1 (5.4) −0.4 (3.7) NA NA ±30.8% ±36.7% 13
VAS Pain (cm), n = 71 6.8 (2.0) 6.8 (1.9) 0.1 (1.6) 1.0 (0.9 to 1.2) 1.7 2.4 2.8 15
KOOS, n = 68
Pain 39.0 (18.7) 36.7 (18.2) 2.3 (10.3) 7.3 (6.2 to 8.8) 12.0 17.0 20.2 19
Symptoms 38.8 (19.2) 39.1 (18.8) −0.4 (12.3) 8.7 (7.4 to 10.5) 40.0 20.2 24.1 22
ADL 43.8 (18.6) 40.2 (19.1) 3.6 (10.6)# 7.5 (6.4 to 9.0) 12.3 17.4 20.8 17
QOL 21.7 (7.7) 23.8 (18.8) −2.7 (13.8) 9.6 (8.2 to 11.6) 15.9 22.4 26.6 44
Hip
6MWT (m), n = 54 339.8 (107.8) 347.3 (105.3) −7.5 (41.6) 29.4 (24.7 to 36.3) 57.7 68.5 81.5 9
TUG* ( s), n = 56 14.0 (7.2) 13.8 (6.6) 0.13 (3.6) NA NA ±37.5% ±44.6% 16
VAS Pain (cm), n = 58 7.1 (2.3) 6.8 (1.9) 0.4 (1.6) 1.2 (1.0 to 1.4) 1.9 2.7 3.3 17
HOOS, n = 56
Pain 36.0 (20.9) 34.4 (20.6) 1.6 (11.0) 7.8 (6.6 to 9.6) 12.8 18.1 21.6 22
Symptoms 42.7 (19.4) 38.1 (21.8) 4.6 (11.6)# 8.2 (6.9 to 10.1) 13.5 19.2 22.7 19
ADL 36.7 (20.9) 34.9 (19.7) 1.8 (9.0) 6.4 (5.4 to 7.8) 10.5 14.8 17.7 17
QOL 20.4 (20.2) 21.8 (21.6) −1.4 (12.5) 8.8 (7.5 to 10.9) 14.6 20.6 24.4 43
Key: SEM, standard error of measurement with 95% confidence level; MDC90 and MDC95, minimal detectable change at the 90% and 95% confidence level; CV%,
co-efficient of variation per cent; 6MWT, six-minute walk test; TUG, timed up-and-go; VAS, visual analogue scale; KOOS, Knee Injury and Osteoarthritis Outcome
Score; HOOS, Hip Disability and Osteoarthritis Outcome Score; ADL, activities of daily living; QOL, quality of life; NA, not applicable (The SEM for TUG is not provided
as it is not derived using the same formula due to its skewed distribution); *TUG data were log-transformed - the corresponding MDC90 and MDC95 are then interpreted as
90% and 95% of the measurements being within a ratio of the original measurement. Note, average Week 1 6MWT above slightly differs from average Week 1 reported for
the comparison between practise and official Week 1 as people who did not have a practise test are included in the average for Week 1 above; #, significantly different,
p < 0.05.
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40.7%.
Discussion
Given the complexities and associated burden of quanti-
fying change from one visit to the next [37], one could
argue why not simply ask the patient if they have im-
proved or worsened. Though the latter approach may be
appealing, in cases where patients may benefit from
reporting deterioration - for example, by being escalated
to arthroplasty surgery - transparency and quantification of
change are required. Further, protracted periods between
assessments will undermine both patient and clinician re-
call, thus, one’s ability to recognise change will be in doubt
[1]. Consequently, an objective method for interpreting
‘change’ is required.
The use of the MDC or other indices of error (or re-
producibility) to determine thresholds for change is an
objective, transparent, simple way to help the clinician
monitor change in the individual with OA. Here, we
provide the MDC for a range of tools with the 6MWT
demonstrating (in a relative sense) the smallest measure-
ment error across the physical and patient-reported tests
assessed. For a change in these tools to be considered‘real’, the patient with knee or hip OA respectively would
need to demonstrate a minimum change (at the 95%
level of confidence) of at least 79 and 81 m for the
6MWT, 3 cm for VAS Pain, 37% and 41% for TUG
(from baseline), 20 and 22 for KOOS and HOOS Pain,
24 and 23 for KOOS and HOOS Symptoms, 21 and 18
for KOOS and HOOS ADL, and 27 and 24 for KOOS
and HOOS QOL subscales.
The magnitude of the week-to-week variation and
MDCs observed here are generally consistent with others.
An earlier study observed that 90% of stable patients with
musculoskeletal problems demonstrated a week-to-week
change of up to 3-points (27%) in their pain rating on an
11-point numeric rating scale [38]. Kennedy et al. [28] re-
ported the MDC90 for the TUG and 6MWT as 2.49 s and
61.34 m in their combined TKA and THA cohort. Our
MDC95 for the KOOS subscales were generally smaller
than the 95% LOA (equivalent to the MDC95) for those
reported by Roos and Toksvig-Larsen [21] which ranged
from 40 (Symptoms) to 60 (Sport and Recreation sub-
scale), whilst our MDC95 for the HOOS subscales were
slightly larger than those reported by Ornetti et al. [39]
which ranged from 10 to 20. In terms of how the agree-
ment indices of the KOOS and HOOS Pain, Symptom




















































































































Figure 1 Bland and Altman Limits of Agreement for the six-minute walk (6MWT), timed up-and-go (TUG), and the visual analogue scale
(VAS) for pain.
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and OHS, we found that the CV% were similar (16%
for both OKS and OHS) [32]. These observations are
interesting as it appears the greater specificities afforded
by the KOOS and HOOS subscales do not guarantee a
smaller measurement error compared to a survey that
does not differentiate contributions made by pain and
functional impairment. It is noteworthy that Impellizzeri
et al. [40] reported a much smaller CV (7%) for the OKS;
this is in part explained by the reverse scoring method
(12–60, with low scores denoting less pain and impair-
ment) used in their study.The MDCs are related to the size of the measurement
error. Our study design does not allow us to determine
whether the error we have observed is due to within-
individual inconsistency in interpretation of survey ques-
tions or subclinical, random biological fluctuations in
the case of timed walk or continuous pain scale mea-
surements. Nevertheless, the fact remains that ‘noise’
in outcome measures – whether they be objectively or
subjectively measured - will undermine the capacity to
monitor disease progression, thus, knowledge of the
MDC of each tool is important for reliable interpretation
of disease status. Our study design also does not allow us








































































































Figure 2 Bland and Altman Limits of Agreement for the Knee Injury and Osteoarthritis Outcome Score (KOOS) and the Hip Disability
and Osteoarthritis Outcome Score (HOOS) subscales. Key: ADL – activities of daily living’ QoL – quality of life.
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the MDC90 and MDC95 values provide clinicians with a
threshold about which ‘true’ change can be considered
to have occurred with considerable confidence, thesethresholds do not denote thresholds for clinically import-
ant changes. Reference to the minimal clinically important
difference (MCID) or minimal important change is ex-
pected to assist the determination of whether change is
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unclear what these values are for all these tools and
their interpretation is contentious given that the MCID
appears to vary according to baseline severity and the
scale used to determine it, and may be time-dependent
[1]. For now, then, the MDCs provide a robust alternative
for interpreting change in the clinic.
We acknowledge the strengths and limitations of our
study. We examined a well-defined cohort likely to be
representative of patients with severe OA waitlisted for
arthroplasty. This contention is supported by the obser-
vations that: 1) the age (68 and 65 yrs), BMI (34 and 31),
and gender (female, 63 and 54%) profiles of the knee and
hip cohorts respectively, reflect those of the entire patient
populations waitlisted for hip or knee arthroplasty at the
two sites involved (age, 69 and 65 yrs; BMI, 34 and 30;
female gender, 68 and 58%, knee and hip cohorts respect-
ively) as per the data each site routinely collects for sub-
mission to the State’s arthroplasty registry (Arthoplasty
Clinical Outcome Registry for NSW, ACORN), and;
2) the baseline physical and patient-reported charac-
teristics of our cohorts reflect those reported elsewhere
[30-32,39-41]. Our sample size exceeded the minimum
recommended sample size for reproducibility studies,
we therefore contend the error margins are credible
estimates and not unduly influenced by an inadequate
sample size. We tested reproducibility under usual care
conditions, thus avoiding overly optimistic error esti-
mates. We have provided reproducibility indices of a
range of tools commonly used to assess knee and hip
OA in the one study allowing comparisons across the
tools. In terms of limitations, we relied on participant
perception of their stability in their health status and
we did not challenge their declarations that they did not
change their medication or physical activity levels between
the two test days. Our assumption around stability of
health status was necessary as there is no known gold
standard for assessing stability in OA [1]. We deliberately
avoided the arbitrary use of stability in one of the tools,
for example VAS joint pain, as the criterion for participant
inclusion in the analysis as this assumes superior reprodu-
cibility of the chosen criterion over all others. Neverthe-
less, 90% (64/71) of the knee and 84% (48/61) of the hip
cohort demonstrated a test-retest difference of ≤ 2 points
in VAS pain (details not shown in Results). Importantly,
these changes align with the weekly changes observed in
the LEAP Trial in a cohort of patients with OA who were
considered stable [42]. Further support for our contention
that the participants were stable is found in the observa-
tions (results not shown) that a change in one measure
was not reliably associated with a change in another, both
in terms of magnitude or direction, suggesting that the
changes were, by and large, ‘noise’. Regarding unchanged
medication and activity levels, participants were awarethat their waitlist assessment was to be conducted over
two assessments and these would be used by the clinicians
to inform their management whilst waiting for surgery.
Thus, we contend participants were unlikely to have
changed their management knowing that the intention
of the assessment (at least from a clinical assessment
perspective) was to assess the appropriateness of their
current management and to provide a new plan if deemed
necessary.
Conclusion
Knowledge of the MDC values for physical performance
and patient-reported tests commonly used to monitor
the severity of OA is necessary for interpreting change
within the individual in the context of daily clinical prac-
tice. The 6MWD demonstrated the smallest measurement
error and, thus, has the capacity to detect the smallest real
change above measurement error, making it (potentially)
the preferred measurement tool.
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